India drugmakers to sell Ozempic copy for $14 a month as Novo patent expires
Indian drug manufacturers are set to launch generic versions of Ozempic for just $14 a month following the expiration of Novo Nordisk's patent.
Large action in the USA. FDA recalled nearly 90,000 bottles of pain medication for children
The FDA has recalled nearly 90,000 bottles of children's pain medication due to reports of black specks and other contaminants.
Weight Loss Will Reduce by ₹3000! Weight Loss Injections Becoming 70% Cheaper
The patent expiration of the weight loss drug Semaglutide on March 20 will lead to a significant price drop of up to 70% for consumers in India.
RIHO UNT ⟩ #59 Pooluniversal medicine
The article humorously claims that the universal cure for everything is simply a good sense of humor.
Pharmacist arrested on suspicion of selling psychiatric and weight loss drugs without prescriptions in Bragança Paulista
A 53-year-old pharmacist was arrested for selling psychiatric medication and weight loss drugs without prescriptions in Bragança Paulista, Brazil.
Ozempic is about to become generic for billions of people
Ozempic will soon be available as a generic drug in many populous countries, significantly lowering its price and improving accessibility.
Elisa Carrió's Praise for Sturzenegger Regarding One of His Recent Measures
Elisa Carrió commended Federico Sturzenegger for eliminating restrictions on obtaining pharmaceutical patents in Argentina.
Infarma President: Europe Must Provide a Boost for Innovation Development
Wiktor Janicki, President of the Innovative Pharmaceutical Employers' Association Infarma, emphasizes the need for Europe to increase investments in clinical research to maintain the pharmaceutical sector as a driver of the European economy.
A. Grzegorzewska, Gedeon Richter: Asian business enters the European drug market
Aneta Grzegorzewska discusses the aggressive strategy of Indian pharmaceutical companies entering the European market with generic products.
A. Grzegorzewska, Gedeon Richter: Asian Business Enters the European Drug Market
The article discusses the aggressive strategy of Indian companies seeking to enter the European generic drug market as Europe aims for greater autonomy in pharmaceuticals.
Indian companies are queuing up to exploit Novo's patent expiry
Indian companies are preparing to launch cheaper weight loss medications following the expiration of Novo Nordisk's patent on semaglutide.
Global drug giants double down on China amid trend to build self-reliant supply chains
Global pharmaceutical companies are investing heavily in China's drug market to establish self-reliant supply chains, with a US$15 billion commitment announced during a recent UK delegation to Beijing.
Ozempic patent expires, but Brazil still lacks national alternatives; new pens may arrive by June
The patent for semaglutide, used in medications like Ozempic, expires soon, but Brazil has yet to see affordable national alternatives, with new versions anticipated by June after regulatory approvals.
Asian Business Enters the Pharmaceutical Market in Europe
The article discusses the importance of pharmaceutical security as a component of national security in Poland, emphasizing the challenges posed by supply chain interruptions due to global conflicts.
Innovations: Europe Must Provide an Impulse
The article discusses the need for Europe to enhance its competitiveness in the life sciences sector amidst increasing global investment competition from the US and China.
UNI-PHARMA and InterMed certified as Top Employers for the fourth consecutive year
The pharmaceutical companies UNI-PHARMA and InterMed have been certified as Top Employers 2026 in Greece for the fourth consecutive year by the Top Employers Institute.
Lawyer Fedorová on the pharmaceutical business / Patient organizations are important for pharmaceutical companies. They are a reservoir of patient stories
Lawyer Katarína Fedorová discusses the pharmaceutical business, the role of patient organizations in lobbying, and the need for critical evaluation of drug efficacy.
A battle after another
The article discusses ongoing conflicts within the Argentine government, particularly focusing on the victory of Federico Sturzenegger in the pharmaceutical industry dispute.
When Illia sought to regulate a conflictive market
The article discusses Argentina's former president Arturo Illia's attempts to regulate the contentious pharmaceutical patent market during his administration.
Medicine shortages loom amid US-Iran conflict
Nigeria's pharmaceutical sector voices concerns over potential medicine shortages due to the US-Iran conflict affecting drug imports and production materials.
Pharmaceuticals ask Sheinbaum to favor purchases of Mexican medicines: 'There will be no subsidies'
The president of the Mexican Association of Pharmaceutical Laboratories urged the government to prioritize local companies in public drug purchases to bolster the national pharmaceutical industry.
The End of the Pharmaceutical Lock: The Story Behind the Patent Resolution that Divided Laboratories for Decades
Argentina has lifted intellectual property restrictions on pharmaceuticals that had been in place since 2012, reflecting a long-standing conflict between domestic and foreign laboratories.
The H-hour for obesity drugs is Friday
The patent for the obesity treatment drug semaglutide will expire in India on Friday, leading to potential price reductions and increased market competition.
The Government deregulated pharmaceutical patents: Sturzenegger's explanation
The Argentine government has deregulated pharmaceutical patents to align local practices with international standards, as announced by Minister Sturzenegger.
Drug Prices: Despite Trump's Deals, Medicines are Cheaper in Germany
Donald Trump's claims of dramatically reduced drug prices in the U.S. are contradicted by evidence showing that medications are cheaper in Germany.
Drug Prices: Despite Trump's Deals, Drugs are Cheaper in Germany
A report argues that despite Donald Trump's claims of dramatically lowered drug prices in the U.S., actual data indicates that medications remain less expensive in Germany.
Middle East war forces pharmaceutical companies to divert critical medicines
The ongoing war in the Middle East is causing pharmaceutical companies to alter distribution routes to ensure that critical medicines reach Australia.
A groundbreaking method in drug production has been discovered. It's the result of a scientist's mistake
Researchers at the University of Cambridge have developed a new method for modifying complex drug molecules using light instead of chemicals, resulting from a laboratory error.
Four arrested with weight loss and sexual stimulants brought from Paraguay in Carmo do Cajuru
Four individuals were arrested in Carmo do Cajuru, Brazil, for illegally transporting weight loss and sexual stimulant medications from Paraguay.
Medicine shortages warning after Iran blockades Strait of Hormuz
Pharmacists in the UK are warning of potential medicine shortages due to Iran's blockade of the Strait of Hormuz, a key shipping route for pharmaceutical ingredients.
Residues of Medicines Accumulate Mainly in Plant Leaves
A study reveals that residues from pharmaceuticals, which humans excrete, accumulate significantly in the leaves of certain crops, posing food safety concerns.
Experts: Economic ties with Russia could be severed by the end of the year, but doing it unilaterally makes no sense
Latvian economist Kārlis Purgailis warns that a rapid cessation of trade with Russia could harm Latvia's economic growth, which heavily relies on exports to Russia, especially in sectors like food and pharmaceuticals.
The risks of the pharmaceutical supply chain: "Logistics are already strained and the cost of air transport has increased by 30% to 100%"
The Spanish pharmaceutical industry is facing potential supply chain disruptions due to geopolitical tensions, particularly concerning dependency on active pharmaceutical ingredients from other countries.
Hypera bets on patent expiration of weight loss pen to boost sales
Hypera's president announced plans for significant sales growth following the expected patent expiration of semaglutide pharmaceuticals.
A Mistake by Scientists Led to a Breakthrough Discovery. An 'Uncut Diamond'
Researchers from Cambridge University have discovered a new drug modification method resulting from a laboratory error, which utilizes light instead of chemical substances.
A Laboratory Mistake Revealed a Breakthrough. A New Way of Creating Drugs
A new drug modification technique has been developed that significantly alters traditional pharmaceutical synthesis processes.
CEO of Boehringer Ingelheim: "Pharma does not need rare earths, Pharma needs bright minds"
The CEO of Boehringer Ingelheim, Shashank Deshpande, expresses concerns over the slow approval process for new drugs in Germany compared to other countries, and emphasizes the need for closer collaboration with India in pharmaceutical research and development.
War in Iran Increases Pressure on Brazil's External Dependency for Medicines and Inputs
The conflict involving the U.S. and Israel against Iran is intensifying concerns over Brazil's reliance on imported pharmaceutical inputs.
EOF recalls three drugs – What problem exists
The EOF has recalled three medications due to various safety and quality concerns.
Korean Pavilion Opens for the First Time at China’s Largest Pharmaceutical and Bio Expo
The Korean pavilion has made its debut at the Bio China 2026 expo, reflecting increased participation from South Korea's pharmaceutical and biopharmaceutical sectors in the rapidly growing Chinese market.
F.A.Z. Einspruch Podcast: Why lawsuits for Corona vaccine damages are becoming easier
The German Federal Court lowers the hurdles for obtaining information about vaccine side effects, making it easier for patients to file claims against pharmaceutical companies for COVID-19 vaccine-related damages.
Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain
Eli Lilly has announced a $3 billion investment plan to enhance its supply chain operations in China, approaching a total investment of nearly $6 billion in the country.
Why Bayer chooses Argentina for science: the country concentrates 60% of its clinical trials in the region
Argentina hosts 60% of Bayer's regional clinical trials, reflecting significant investments in scientific capital.
Farewell to Sahin and Türeci: A Wise Decision by the BioNTech Founders
Ugur Sahin and Özlem Türeci's decision to step back from the operational leadership of BioNTech is seen as a strategic move in their ongoing legacy in pharmaceuticals.
EMS plans to launch a generic version of Ozempic by September
Brazilian pharmaceutical EMS aims to introduce its generic version of Ozempic to the market by September, contingent on the approval from health agency Anvisa within the next 60 days.
Why 'Brazilian Ozempic' may take time and the patent expiration won't lower prices
The expiration of the semaglutide patent in Brazil is unlikely to lead to immediate price reductions for Ozempic due to regulatory and manufacturing challenges.
Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn
Experts warn that the pipeline for new drugs to combat superbugs has shrunk significantly and could lead to a doubling of deaths from drug-resistant infections by 2050.
Andris Jegorovs has left the position of board member at the Latvian drug manufacturer 'Olpha'
Andris Jegorovs resigns as a board member of Latvian pharmaceutical company Olpha amid declining revenue and profits.
Corona Vaccine Damage: Federal Court Helps Injured Patients
A German court ruled in favor of patients suffering from vaccine side effects, easing access to information from pharmaceutical companies regarding potential risks.
Trump's Rx plan promises savings, but economists see a hidden trade-off
President Trump's plan to reduce prescription drug prices through the TrumpRx platform may lead to immediate savings but poses potential risks to the future development of new drugs according to economists.